Literature DB >> 18446056

Gene network and canonical pathway analysis in prostate cancer: a microarray study.

Hakan Savli1, Attila Szendröi, Imre Romics, Balint Nagy.   

Abstract

The molecular mechanism playing a role in the development of prostate cancer (PCA) is not well defined. We decided to determine the changes in gene expression in PCA tissues and to compare them to those in non-cancerous samples. Prostate tissue samples were collected by needle biopsy from 21 PCA and 10 benign prostate hyperplasic (BPH) patients. Total RNA was isolated, cDNA was synthesized, and gene expression levels were determined by microarray method. In the progression to PCA, 738 up-regulated and 515 down-regulated genes were detected in samples. Analysis using Ingenuity Pathway Analysis (IPA) software revealed that 466 network and 423 functions-pathways eligible genes were up-regulated, and 363 network and 342 functions-pathways eligible genes were down-regulated. Up-regulated networks were identified around IL-1beta and insulin-like growth factor-1 (IGF-1) genes. The NFKB gene was centered around two up- and down-regulated networks. Up-regulated canonical pathways were assigned and four of them were evaluated in detail: acute phase response, hepatic fibrosis, actin cytoskeleton, and coagulation pathways. Axonal guidance signaling was the most significant down-regulated canonical pathway. Our data provide not only networks between the genes for understanding the biologic properties of PCA but also useful pathway maps for future understanding of disease and the construction of new therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18446056      PMCID: PMC2679302          DOI: 10.3858/emm.2008.40.2.176

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  47 in total

1.  Gene expression analysis of 1,25(OH)2D3-dependent differentiation of HL-60 cells: a cDNA array study.

Authors:  Hakan Savli; Yan Aalto; Bálint Nagy; Sakari Knuutila; Seppo Pakkala
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

2.  Prostate-specific antigen levels among cirrhotic patients.

Authors:  M Akdogan; B S Hassoun; A Gurakar; K El-Sahwi; A Jazzar; H Wright; A Sebastian; B Nour
Journal:  Int J Biol Markers       Date:  2002 Jul-Sep       Impact factor: 2.659

3.  Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.

Authors:  H L Liu; R Gandour-Edwards; P N Lara; R de Vere White; J M LaSalle
Journal:  Cancer J       Date:  2001 Sep-Oct       Impact factor: 3.360

4.  PSK, a novel STE20-like kinase derived from prostatic carcinoma that activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway and regulates actin cytoskeletal organization.

Authors:  T M Moore; R Garg; C Johnson; M J Coptcoat; A J Ridley; J D Morris
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

5.  Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix.

Authors:  Tobias Engl; Borna Relja; Christa Blumenberg; Iris Müller; Eva M Ringel; Wolf-Dietrich Beecken; Dietger Jonas; Roman A Blaheta
Journal:  Life Sci       Date:  2005-11-02       Impact factor: 5.037

6.  Alternative splicing of fibroblast growth factor receptors in human prostate cancer.

Authors:  B Kwabi-Addo; F Ropiquet; D Giri; M Ittmann
Journal:  Prostate       Date:  2001-02-01       Impact factor: 4.104

7.  E-selectin up-regulation allows for targeted drug delivery in prostate cancer.

Authors:  Vinay Bhaskar; Debbie A Law; Eric Ibsen; Danna Breinberg; Kellie M Cass; Robert B DuBridge; Ferdinand Evangelista; Susan M Henshall; Peter Hevezi; Jennifer C Miller; Melody Pong; Rick Powers; Peter Senter; David Stockett; Robert L Sutherland; Ursula von Freeden-Jeffry; Dorian Willhite; Richard Murray; Daniel E H Afar; Vanitha Ramakrishnan
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

Review 8.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

Authors:  Peter C Heinrich; Iris Behrmann; Serge Haan; Heike M Hermanns; Gerhard Müller-Newen; Fred Schaper
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

9.  A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors.

Authors:  Evangelia A Papakonstanti; Marilena Kampa; Elias Castanas; Christos Stournaras
Journal:  Mol Endocrinol       Date:  2003-01-23

10.  Human epidermal receptor-2 expression in prostate cancer.

Authors:  Benjamin F Calvo; Aaron M Levine; Mavie Marcos; Qu F Collins; Mary V Iacocca; Laura S Caskey; Christopher W Gregory; Yuhua Lin; Young E Whang; H Shelton Earp; James L Mohler
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531

View more
  30 in total

1.  Analysis of the specific pathways and networks of prostate cancer for gene expression profiles in the Chinese population.

Authors:  Jia-hong Chen; Hui-chan He; Fu-neng Jiang; Julia Militar; Petor-yang Ran; Guo-qiang Qin; Chao Cai; Xi-Bin Chen; Jin Zhao; Zi-yao Mo; Yan-ru Chen; Jian-guo Zhu; Xingyin Liu; Wei-de Zhong
Journal:  Med Oncol       Date:  2011-10-30       Impact factor: 3.064

2.  Differential alternative splicing of human transglutaminase 4 in benign prostate hyperplasia and prostate cancer.

Authors:  Sung-Yup Cho; Kyungho Choi; Ju-Hong Jeon; Chai-Wan Kim; Dong-Myung Shin; Jong Bouk Lee; Sang Eun Lee; Choung-Soo Kim; Jeong-Soo Park; Eui Man Jeong; Gi-Yong Jang; Kye-Yong Song; In-Gyu Kim
Journal:  Exp Mol Med       Date:  2010-04-30       Impact factor: 8.718

3.  Research resource: estrogen-driven prolactin-mediated gene-expression networks in hormone-induced prostatic intraepithelial neoplasia.

Authors:  Neville N C Tam; Carol Y Y Szeto; Johannes M Freudenberg; Amy N Fullenkamp; Mario Medvedovic; Shuk-Mei Ho
Journal:  Mol Endocrinol       Date:  2010-09-22

4.  Palmatine inhibits growth and invasion in prostate cancer cell: Potential role for rpS6/NFκB/FLIP.

Authors:  Heather G Hambright; Izhar Singh Batth; Jianping Xie; Rita Ghosh; Addanki Pratap Kumar
Journal:  Mol Carcinog       Date:  2014-07-07       Impact factor: 4.784

5.  G protein betagamma subunits regulate cell adhesion through Rap1a and its effector Radil.

Authors:  Syed M Ahmed; Avais M Daulat; Alexandre Meunier; Stephane Angers
Journal:  J Biol Chem       Date:  2010-01-04       Impact factor: 5.157

Review 6.  Serum amyloid A: an acute-phase protein involved in tumour pathogenesis.

Authors:  E Malle; S Sodin-Semrl; A Kovacevic
Journal:  Cell Mol Life Sci       Date:  2009-01       Impact factor: 9.261

7.  Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N'-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino}ethyl)guanidine (SB706504).

Authors:  Lauren M Kent; Lucy J C Smyth; Jonathan Plumb; Chris L Clayton; Steve M Fox; David W Ray; Stuart N Farrow; Dave Singh
Journal:  J Pharmacol Exp Ther       Date:  2008-11-12       Impact factor: 4.030

8.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

9.  A network flow approach to predict drug targets from microarray data, disease genes and interactome network - case study on prostate cancer.

Authors:  Shih-Heng Yeh; Hsiang-Yuan Yeh; Von-Wun Soo
Journal:  J Clin Bioinforma       Date:  2012-01-13

10.  Plasma Dehydroepiandrosterone Sulfate and Cardiovascular Disease Risk in Older Men and Women.

Authors:  Xiaoming Jia; Caroline Sun; Olive Tang; Ivan Gorlov; Vijay Nambi; Salim S Virani; Dennis T Villareal; George E Taffet; Bing Yu; Jan Bressler; Eric Boerwinkle; B Gwen Windham; James A de Lemos; Kunihiro Matsushita; Elizabeth Selvin; Erin D Michos; Ron C Hoogeveen; Christie M Ballantyne
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.